Mohammad, A. J., Jacobsson, L. T., Mahr, A. D., et al. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology 2007; 46: 1329–37.Google Scholar

Watts, R. A., Mahr, A., Mohammad, A. J., et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015; 30: 14–22.CrossRefGoogle ScholarPubMed

Berti, A., Cornec, D., Crowson, C. S., et al. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: A twenty-year US population-based study. Arthritis Rheumatol. 2017; 69: 2338–50.Google Scholar

Li, J., Cui, Z., Long, J. Y., et al. The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. Arthritis Res Ther. 2018; 20: 226.Google Scholar

Canney, M., O’Hara, P. V., McEvoy, C. M., et al. Spatial and temporal clustering of anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2016; 11: 1392–9.Google Scholar

Ma, R., Cui, Z., Hu, S. Y., et al. The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease. PLoS ONE 2014; 21: 9.Google Scholar

Sethi, S., Zand, L., De Vriese, A. S., et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: Results of a proteomic analysis. Nephrol Dial Transplant. 2017; 32: 139–45.Google Scholar

Furuta, S., Jayne, D. R.. Antineutrophil cytoplasm antibody-associated vasculitis: Recent developments. Kidney Int. 2013; 84: 244–9.CrossRefGoogle ScholarPubMed

Savage, C. O., Pusey, C. D., Bowman, C., et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J. 1986; 292: 301–4.Google Scholar

Cui, Z., Zhao, J., Jia, X. Y., et al. Anti-glomerular basement membrane disease: Outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine. 2011; 90: 303–11.CrossRefGoogle Scholar

Berden, A. E., Ferrario, F., Hagen, E. C., et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010; 21: 1628–36.Google Scholar

Brix, S. R., Noriega, M., Tennstedt, P., et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018; 94: 1177–88.Google Scholar

Jones, R. B., Tervaert, J. W., Hauser, T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010; 363: 211–20.Google Scholar

Stone, J. H., Merkel, P. A., Spiera, R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363: 221–32.Google Scholar

Yates, M., Watts, R. A., Bajema, I. M., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016; 75: 1583–94.Google Scholar

Walsh, M., Merkel, P. A., Peh, C. A., et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020; 382: 622–31.CrossRefGoogle ScholarPubMed

Jayne, D. R. W., Merkel, P. A., Schall, T. J., et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021; 384: 599–609.Google Scholar

Soveri, I., Mölne, J., Uhlin, F., et al. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019; 96: 1234–8.Google Scholar

Zipfel, P. F., Wiech, T., Rudnick, R., et al. Complement inhibitors in clinical trials for glomerular diseases. Front Immunol. 2019; 10: 2166.CrossRefGoogle ScholarPubMed

Gavriilaki, E., Anagnostopoulos, A., Mastellos, D. C.. Complement in thrombotic microangiopathies: Unraveling Ariadne’s thread in to the labyrinth of complement therapeutics. Front Immunol. 2019; 10: 337.CrossRefGoogle Scholar

Ardissino, G., Salardi, S., Colombo, E., et al. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr. 2016; 175: 465–73.Google Scholar

Nester, C. M., Thomas, C. P.. Atypical hemolytic uremic syndrome: What is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012; 2012: 617–25.CrossRefGoogle Scholar

Elhadad, S., Chapin, J., Copertino, D., et al. MASP2 levels are elevated in thrombotic microangiopathies: Association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021; 203: 96–104.CrossRefGoogle ScholarPubMed

Coppo, P., Bubenheim, M., Azoulay, E., et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021; 137: 733–42.CrossRefGoogle ScholarPubMed

Brocklebank, V., Wood, K. M., Kavanagh, D.. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018; 13: 300–17.CrossRefGoogle ScholarPubMed

Conway, E. M., Pryzdia, E. L. G.. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost. 2020; 18: 2812–22.CrossRefGoogle ScholarPubMed

Cines, D. B., Bussel, J. B.. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021; 384: 2254–6.Google Scholar

Holz, J. B.. The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2012; 46: 343–6.Google Scholar

Rao, G.. Diagnosis, epidemiology, and management of hypertension in children. Pediatrics. 2016; 138: 3616.CrossRefGoogle ScholarPubMed

Mills, K. T., Bundy, J. D., Tanika, N., et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441–50.Google Scholar

Lewington, S., Clarke, R., Qizilbash, N., et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903–13.Google ScholarPubMed

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127–e248. doi: 10.1016/j.jacc.2017.11.006. Epub 2017 Nov 13. Erratum in: J Am Coll Cardiol. 2018 May 15;71 (19):2275–2279. PMID: 29146535.Google Scholar

Patel, P. A., Cahill, A. M.. Renovascular hypertension in children. CVIR Endovasc. 2021; 4: 10.CrossRefGoogle ScholarPubMed

Riedlinger, W. F., Kissane, J. M., Gibfried, M., Liapis, H.. Congenital bilateral renal arteriovenous malformation: An unrecognized cause of renal failure. Pediatr Dev Pathol. 2004; 7(3): 285–9.Google Scholar

Watanabe, T.. Kidney and urinary tract involvement in kawasaki disease. Int J Pediatr. 2013; 2013: 831834.CrossRefGoogle ScholarPubMed

Whelton PK, Carey RM, Aronow WS, etal ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248.Google Scholar

Calatroni M, Consonni F, Allinovi M, etal. Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. Clin J Am Soc Nephrol. 2021;16(7):1043–51.Google Scholar